{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Liu Q"],"pubmed_abstract":["G protein-coupled receptors (GPCRs) are a group of seven-transmembrane receptor proteins that have proven to be successful drug targets. Antibodies are becoming an increasingly promising modality to target these receptors due to their unique properties, such as exquisite specificity, long half-life, and fewer side effects, and their improved pharmacokinetic and pharmacodynamic profiles compared to peptides and small molecules, which results from their more favorable biodistribution. To date, there are only two US Food and Drug Administration-approved GPCR antibody drugs, namely erenumab and mogamulizumab, and this highlights the challenges encountered in identifying functional antibodies against GPCRs. Utilizing Twist's precision DNA writing technologies, we have created a GPCR-focused pha"],"journal":["mAbs"],"pagination":["1893425"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7971233"],"repository":["biostudies-literature"],"pubmed_title":["Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control."],"pmcid":["PMC7971233"],"pubmed_authors":["Lai J","Yuan TZ","Axelrod F","Kwan E","Liu Q","Hasdemir B","Garg P","Hernandez AGL","Wang L","Paruthiyil S","K Sato A","Tuscano E","Keane E","Sever E","Szot G"],"additional_accession":[]},"is_claimable":false,"name":"Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.","description":"G protein-coupled receptors (GPCRs) are a group of seven-transmembrane receptor proteins that have proven to be successful drug targets. Antibodies are becoming an increasingly promising modality to target these receptors due to their unique properties, such as exquisite specificity, long half-life, and fewer side effects, and their improved pharmacokinetic and pharmacodynamic profiles compared to peptides and small molecules, which results from their more favorable biodistribution. To date, there are only two US Food and Drug Administration-approved GPCR antibody drugs, namely erenumab and mogamulizumab, and this highlights the challenges encountered in identifying functional antibodies against GPCRs. Utilizing Twist's precision DNA writing technologies, we have created a GPCR-focused pha","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan-Dec","modification":"2026-04-07T15:48:07.782Z","creation":"2026-04-07T14:57:49.722Z"},"accession":"S-EPMC7971233","cross_references":{"pubmed":["33706686"],"doi":["10.1080/19420862.2021.1893425"]}}